Form 4: Corvus Pharmaceuticals Insider Trades
Statement of Changes in Beneficial Ownership
Richard A. Miller, President and CEO of Corvus Pharmaceuticals, reported transactions involving the acquisition and disposition of company stock.
Summary
- Richard A. Miller, President and CEO and Director of Corvus Pharmaceuticals, Inc., reported transactions on May 18, 2026.
- Miller acquired 5,000 shares of common stock at a price of $12.05 per share and an additional 1,932 shares at $12.01 per share.
- Following these acquisitions, Miller beneficially owned 1,195,035 shares.
- The filing also indicates a disposition of 1,136,707 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions with both acquisitions and a significant disposition, offering no strong indication of positive or negative future performance.
Positives
- Acquisition of 6,932 shares of Corvus Pharmaceuticals common stock by the President and CEO, indicating potential confidence in the company.
- The reporting person, Richard A. Miller, holds a significant number of shares, with 1,195,035 shares beneficially owned after the reported transactions.
Negatives
- A disposition of 1,136,707 shares of common stock was reported, which could indicate a reduction in the reporting person's direct stake or a rebalancing of holdings.
Future Outlook
No specific forward-looking statements or guidance were provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the buying and selling activities of company executives and directors. These transactions can offer insights into management's perception of the company's valuation and future prospects.
Related Party Transactions
- Richard A. Miller, President and CEO, is also a Trustee of the Miller-Horning Family Trust, which holds shares of Corvus Pharmaceuticals.
Stakeholder Impact
- Shareholders: The acquisition of shares by the CEO may be viewed positively, while the disposition could raise questions about management's confidence or need for liquidity.
- Employees: Insider trading activity can influence employee morale and perception of company leadership.
- Creditors: No direct impact is indicated.
Key Dates
| Date | Description |
|---|---|
| 01/25/1985 | Date of the Miller-Horning Family Trust. |
| 05/18/2026 | Earliest transaction date reported for stock acquisitions and disposition. |
| 05/20/2026 | Signature date of the filing. |
Keywords
Corvus Pharmaceuticals, CRVS, Form 4, Insider Trading, Stock Transaction, Beneficial Ownership, Richard A. Miller, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.